idraparinux

Idraparinux is a long-acting, synthetic pentasaccharide that acts as a selective, indirect inhibitor of Factor Xa. It is a hypermethylated derivative of fondaparinux, designed with a significantly extended half-life of approximately 80 hours, which allows for once-weekly subcutaneous administration. The molecule binds with high affinity to antithrombin III, inducing a conformational change that dramatically accelerates the neutralization of Factor Xa, thereby preventing thrombin generation and fibrin clot formation. Developed by Sanofi, idraparinux was evaluated in large-scale Phase 3 clinical trials (such as AMADEUS and BOREALIS) for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation. However, its clinical development was discontinued due to a high incidence of major bleeding events and the lack of a specific reversal agent, leading to the development of its biotinylated successor, idrabiotaparinux.

Other names

idraparinux sodium